The announcement that inhaled insulin will soon be available in India has understandably generated a lot of excitement and ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the ...

Fintel reports that on January 10, 2025, Roth MKM initiated coverage of Verona Pharma plc - Depositary Receipt () ...

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

Phillips Medisize parent company Molex has completed its acquisition of Vectura from a subsidiary of cigarette maker Philip ...

"The acquisition of Vectura reflects our commitment to advancing industry-leading medical capabilities for our customers," said Joe Nelligan, CEO, Molex, which acquired Phillips Medisize in 2016.

When patients cannot adhere to inhaler instructions — whether ... Nebulized versus dry powder long-acting muscarinic antagonist bronchodilators in patients with COPD and suboptimal peak inspiratory ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...